Identification and synthesis of 2,7-diamino-thiazolo[5,4-d]pyrimidine derivatives as TRPV1 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 1, 2009, Pages 40-46

  Lebsack, Alec D ^a   Branstetter, Bryan J ^a   Hack, Michael D ^a   Xiao, Wei ^a   Peterson, Matthew L ^b   Nasser, Nadia ^a   Maher, Michael P ^a   Ao, Hong ^a   Bhattacharya, Anindya ^a   Kansagara, Mena ^a   Scott, Brian P ^a   Luo, Lin ^a   Rynberg, Raymond ^a   Rizzolio, Michele ^a   Chaplan, Sandra R ^a   Wickenden, Alan D ^a   Guy Breitenbucher, J ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b TransForm Pharmaceuticals   (United States)

Author keywords

Antagonists; Thiazolo pyrimidine; TRPV1

Indexed keywords

2,7 DIAMINOTHIAZOLO[5,4 D]PYRIMIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYPERALGESIA; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; HYPERALGESIA; PYRIMIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TREATMENT OUTCOME; TRPV CATION CHANNELS;

RATTUS;

EID: 57749118683     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.024     Document Type: Article

References (30)

1. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., and Julius D. Nature 389 (1997) 816
2. Montell C., Birnbaumer L., Flockerzi V., Bindels R.J., Bruford E.A., Caterina M.J., Clapham D.E., Harteneck C., Heller S., Julius D., Kojima I., Mori Y., Penner R., Prawitt D., Scharenberg A.M., Schultz G., Shimizu N., and Zhu M.X. Mol. Cell 9 (2002) 229
3. Gunthorpe M.J., Benham C.D., Randall A., and Davis J.B. Trends Pharmacol. Sci. 23 (2002) 183
4. Szallasi A., and Blumberg P.M. Pharmacol. Rev. 51 (1999) 159
5. Appendino G., Munoz E., and Fiebich B.L. Expert Opin. Ther. Patents 13 (2003) 1825
6. Caterina M.J., and Julius D. Annu. Rev. Neurosci. 24 (2001) 487
7. See Refs. 1,2, and 6b.
8. Caterina M.J., Leffler A., Malmberg A.B., Martin W.J., Trafton J., Petersen-Zeitz K.R., Koltzenburg M., Basbaum A.I., and Julius D. Science 288 (2000) 306
9. Davis J.B., Gray J., Gunthorpe M.J., Hatcher J.P., Davey P.T., Overend P., Harries M.H., Latcham J., Clapham C., Atkinson K., Hughes S.A., Rance K., Grau E., Harper A.J., Pugh P.L., Rogers D.C., Bingham S., Randall A., and Sheardown S.A. Nature 405 (2000) 183
10. For recent TRPV1 reviews see. Breitenbucher J.G., Chaplan S.R., and Carruthers N.I. Annu. Rep. Med. Chem. 40 (2005) 185
11. Westaway S.A. J. Med. Chem. 50 (2007) 2589
12. Szallasi A., and Gharat L.A. Expert Opin. Ther. Patents 18 (2008) 159
13. The synthesis and structure-activity relationships of 5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidines as TRPV1 antagonists will be reported in due course. In addition to our own efforts, preparations of 5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidines as TRPV1 receptor modulators have been reported in the patent literature. (a) Kelly, M. G.; Janagani, S.; Wu, G.; Kincaid, J.; Lonergan, D.; Fang, Y.; Wei, Z. PCT Int. Appl. WO2005066171, 2005. (b) Norman, M. H.; Ognyanov, V. I.; Pettus L. H. US Patent 0165032, 2005. (c) Lee, C.; Brown, B. S.; Keddy, R. G.; Perner, R. J.; Koenig, J. R. PCT Int. Appl. WO2006062981, 2006.
14. For accounts of TRPV1 antagonists with other relevant heterocyclic cores see: (a) Bakthavatchatam, R.; Blum, C. A.; Brielmann, H. L.; Caldwell, T. M.; De Lombaert, S. PCT Int. Appl. WO2003062209, 2003. (b) Allison, B. D.; Branstetter, B. J.; Breitenbucher, J. G.; Hack, M. D.;Hawryluk, N. A.; Lebsack, A. D.; McClure, K. J.; Merit, J. E. PCT Int. Appl. WO2007109355, 2007.
15. For single step synthesis of 2-amino-7-chloro-thiazolo[5,4-d]pyrimidine see. Liu J., Patch R.J., Schubert C., and Player M.R. J. Org. Chem. 70 (2005) 10194
16. Lebsack, A. D.; Branstetter, B. J.; Xiao, W.; Hack, M. D.; Nasser, N.; Maher, M. P.; Ao, H.; Bhattacharya, A.; Kansagara, M.; Scott, Brian P.; Luo, L.; Chaplan, S. R.; Wickenden, A. D.; Breitenbucher, J. G. Abstracts of Papers, 236th ACS National Meeting, Philadelphia, PA, United States, August 17-21, 2008; MEDI-467.
17. Thiazole-4-carboxamides containing a 2,6-dichlorophenyl group have been reported as TRPV1 antagonists. Xi N., Bo Y., Doherty E.M., Fotsch C., Gavva N.R., Han N., Hungate R.W., Klionsky L., Liu Q., Tamir R., Xu S., Treanor J.J.S., and Norman M.H. Bioorg. Med. Chem. Lett. 15 (2005) 5211
18. Bhattacharya A., Scott B.P., Nasser N., Ao H., Maher M.P., Dubin A.E., Swanson D.M., Shankley N.P., Wickenden A.D., and Chaplan S.R. J. Pharmacol. Exp. Ther. 323 (2007) 665
19. MOE (The Molecular Operating Environment) Version 2006.08, software available from Chemical Computing Group Inc., 1010 Sherbrooke Street West, Suite 910, Montreal, Canada H3A 2R7. http://www.chemcomp.com.
20. MacroModel, version 9.5, Schrodinger, LLC, New York, NY, 2007.
21. Jaguar, version 7.0, Schrodinger, LLC, New York, NY, 2007.
22. ROCS (Rapid Overlay of Chemical Structures), version 2.3.1, OpenEye Scientific Software, Inc., Santa Fe, NM, USA, http://www.eyesopen.com, 2007.
23. Branstetter, B. J.; Breitenbucher, J. G.; Lebsack, A. D.; Xiao, W. US Patent Appl. 2008, 004253.
24. 13C HSQC and HMBC were used to confirm the structure of compound 8 and therefore 7b. In the HMBC, a strong 3-bond coupling was observed between the proton on the N-methyl and the two adjacent quaternary carbons for compound 8.{A figure is presented}
25. The authors have deposited coordinates for this compound with the Cambridge Crystallographic Data Centre. The coordinates of 3 are CCDC 702151.
26. Liebeskind L.S., and Srogl J. Org. Lett. 4 (2002) 979
27. Binnun, E.; Johnson, S. G.; Connolly, P. J.; Middleton, S. A.; Moreno-Mazza, S. J.; Lin, R.; Pandey, N. B.; Wetter, S. K. PCT Int. Appl. WO 2007019191, 2007.
28. The solubility assay was conducted in a 96-well format using DMSO stock solutions (10 mM of compound). DMSO was evaporated and residual solids were re-suspended in fasted-state simulated intestinal fluid (SIF; pH 6.8) or simulated gastric fluid (SGF; pH 1.2) for 3 days. The resulting mixtures were filtered and analyzed by HPLC against external standards.
29. When tested at 1 or 10 μM, compound 3 afforded no significant hits in a Cerep panel of 60 targets.
30. Under anesthesia, 100 μL of 1% carrageenan (Sigma) in saline was injected subcutaneously into the plantar surface of the hind paw. For methods and references on the thermal hyperalgesia testing see: Swanson, D. M.; Dubin, A. E.; Shah, C.; Nasser, N.; Chang, L.; Dax, S. L.; Jetter, M.; Breitenbucher, J. G.; Liu, C.; Mazur, C.; Lord, B.; Gonzales, L.; Hoey, K.; Rizzolio, M.; Bogenstaetter, M.; Codd, E. E.; Lee, D. H.; Zhang, S.; Chaplan, S. R.; Carruthers, N. I. J. Med. Chem. 2005, 48, 1857.